Novo Nordisk A/S (NYSE:NVO) Shares Acquired by Coppell Advisory Solutions LLC

Coppell Advisory Solutions LLC lifted its stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 31.6% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 28,048 shares of the company's stock after buying an additional 6,732 shares during the quarter. Coppell Advisory Solutions LLC's holdings in Novo Nordisk A/S were worth $2,405,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of NVO. Victory Capital Management Inc. increased its position in shares of Novo Nordisk A/S by 58.5% during the fourth quarter. Victory Capital Management Inc. now owns 62,897 shares of the company's stock worth $5,410,000 after purchasing an additional 23,223 shares in the last quarter. Norman Fields Gottscho Capital Management LLC boosted its holdings in Novo Nordisk A/S by 45.3% in the 4th quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company's stock valued at $5,482,000 after purchasing an additional 19,870 shares in the last quarter. Bryn Mawr Capital Management LLC boosted its position in shares of Novo Nordisk A/S by 358.8% during the 4th quarter. Bryn Mawr Capital Management LLC now owns 38,898 shares of the company's stock worth $3,346,000 after purchasing an additional 30,420 shares in the last quarter. Versant Capital Management Inc acquired a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at about $86,000. Finally, Talbot Financial LLC purchased a new stake in shares of Novo Nordisk A/S during the 4th quarter worth approximately $4,066,000. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Stock Down 0.9 %

Novo Nordisk A/S stock traded down $0.56 during midday trading on Friday, hitting $62.07. The stock had a trading volume of 7,826,465 shares, compared to its average volume of 6,109,718. Novo Nordisk A/S has a 12 month low of $57.00 and a 12 month high of $148.15. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The stock has a market cap of $278.54 billion, a P/E ratio of 18.87, a P/E/G ratio of 0.90 and a beta of 0.61. The business has a fifty day moving average price of $73.62 and a 200 day moving average price of $89.61.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, topping analysts' consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Research analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently disclosed a semi-annual dividend, which was paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st were given a dividend of $0.7874 per share. The ex-dividend date was Monday, March 31st. This is an increase from Novo Nordisk A/S's previous semi-annual dividend of $0.51. This represents a dividend yield of 1.2%. Novo Nordisk A/S's payout ratio is currently 49.54%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on NVO shares. BNP Paribas assumed coverage on shares of Novo Nordisk A/S in a research report on Tuesday, April 15th. They issued an "underperform" rating on the stock. StockNews.com upgraded Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a research note on Friday. Guggenheim lowered shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a report on Thursday, April 17th. UBS Group upgraded Novo Nordisk A/S from a "sell" rating to a "buy" rating in a report on Wednesday, January 8th. Finally, Morgan Stanley started coverage on Novo Nordisk A/S in a report on Wednesday, February 12th. They issued an "equal weight" rating for the company. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $135.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.